• Magnetic Stimulation Targets GABAA ε Subunit in Schizophreni

  2026-05-05

  This study demonstrates that precise magnetic stimulation of the left prelimbic cortex downregulates the GABAA receptor ε subunit, reversing schizophrenia-like behaviors and synaptic deficits in mouse models. The work reveals a mechanistic link between GABRE modulation and circuit-level recovery, offering new molecular targets for advanced neuromodulation strategies in schizophrenia research.

• Deoxynivalenol Liver Injury: Mitophagy Overactivation and Nr

  2026-05-04

  This study elucidates how deoxynivalenol (DON), a common mycotoxin, induces liver injury by overactivating PINK1/Parkin-mediated mitophagy and suppressing the p62-Keap1-Nrf2 cytoprotective pathway. The findings clarify the mechanistic links between mitochondrial quality control, antioxidant defense, and hepatotoxicity, informing improved model development and targeted interventions.

• Light and Brassinosteroids Independently Regulate Arabidopsi

  2026-05-04

  This study reveals that light and brassinosteroids modulate Arabidopsis seedling root growth in largely independent ways. The findings clarify how endogenous and exogenous brassinolide suppress root elongation regardless of light, while light consistently promotes root growth, providing a nuanced understanding for researchers modeling plant development or stress responses.

• HO-1 Modulation and HBV Replication: Insights from Isochloro

  2026-05-03

  This article reviews a study revealing how isochlorogenic acid A disrupts hepatitis B virus (HBV) replication by upregulating heme oxygenase-1 (HO-1) and altering reactive oxygen species (ROS) dynamics. The findings have broad implications for antiviral strategy development and mechanistic research into HO-1-mediated pathways.

• LY2603618: Chk1 Inhibitor Workflows for DNA Damage Research

  2026-05-02

  LY2603618 is a potent, highly selective Chk1 inhibitor that enables precise modulation of DNA damage response and cell cycle arrest at the G2/M phase. This guide delivers actionable protocols, troubleshooting strategies, and experimental insights for leveraging LY2603618 in cancer research, with a spotlight on synergy in non-small cell lung cancer models.

• SM-164: Bivalent Smac Mimetic for Precision Apoptosis Induct

  2026-05-02

  SM-164 empowers cancer researchers with rapid, tunable apoptosis induction by targeting IAPs, enabling high-sensitivity, reproducible results in both cell-based and in vivo models. This guide translates recent advances in signalosome assembly and mechanistic insights into actionable experimental workflows and troubleshooting tips for maximizing your outcomes.

• Aumolertinib Plus Radiation in EGFR-Mutant NSCLC Brain Metas

  2026-05-01

  This study systematically evaluated the therapeutic benefit of combining the third-generation EGFR-TKI aumolertinib with ionizing radiation in models of EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases. The work offers new mechanistic and preclinical evidence supporting the synergy of this combination, with implications for overcoming therapeutic barriers in brain metastasis management.

• GluN2A/2B Modulate Connexins in Orofacial Allodynia via MAPK

  2026-04-30

  This study unveils how NMDA receptor subunits GluN2A and GluN2B differentially regulate connexin and pannexin expression in the trigeminal ganglion, contributing to orofacial inflammatory allodynia during TMJ inflammation. By dissecting intracellular signaling, it reveals distinct roles for these subunits in peripheral sensitization, offering new directions for targeted pain interventions.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-04-30

  A novel glabridin-gold(I) complex (6d) was developed to target both thioredoxin reductase (TrxR) and MAPK signaling, achieving dual immunomodulation in liver cancer models. The study demonstrates that 6d synergistically enhances dendritic cell maturation, reduces immunosuppressive cell populations, and modulates PD-L1/GzmB expression, indicating potential for improved cancer immunotherapy outcomes.

• LY2109761: Strategic TGF-β Pathway Modulation for Translatio

  2026-04-29

  Explore how LY2109761, a dual TGF-β receptor kinase inhibitor, empowers translational researchers to dissect and therapeutically modulate the invasion-proliferation axis in glioblastoma and pancreatic cancer, with unique mechanistic insights drawn from recent advances in post-translational regulation and radiosensitization.

• Ornithine-ZBTB7A Axis in Realgar-Induced CNS Toxicity: New I

  2026-04-29

  This study uncovers how realgar-derived arsenic disrupts both hepatic ornithine metabolism and astrocyte glycolysis via the OTC-ornithine-ZBTB7A pathway, leading to central nervous system toxicity. The findings highlight mechanistic links between liver dysfunction and neurotoxicity, offering new experimental frameworks for metabolic and CNS toxicity research.

• Porous Graphene LDI-MSI Reveals Brain Lipid Asymmetry Post-E

  2026-04-28

  This study introduces a porous laser-induced graphene (LIG) substrate for matrix-free laser desorption/ionization mass spectrometry imaging (LDI-MSI), enabling unprecedented 3 μm spatial resolution and streamlined workflows. Application of this platform uncovers dynamic, lateralized lipid metabolism in mouse brains following acute ethanol intoxication, offering new insights into spatially resolved metabolic responses.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization in CAC

  2026-04-28

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine compound, inhibits the progression of colitis-associated colorectal cancer (CAC) by shifting macrophage polarization toward the M1 phenotype through TLR4 pathway activation. This mechanistic insight highlights the therapeutic potential of targeting macrophage plasticity in the tumor microenvironment for CAC management.

• Gamithromycin (BA1074): Tissue Distribution and PK/PD Insigh

  2026-04-27

  Explore the unique tissue distribution and advanced pharmacokinetic/pharmacodynamic (PK/PD) properties of Gamithromycin (BA1074) in veterinary research. This article reveals new, evidence-backed considerations for respiratory infection models, setting it apart from standard mechanism or protocol guides.

• Simvastatin (Zocor): Mechanistic Evidence and Experimental U

  2026-04-27

  Simvastatin (Zocor) is a potent HMG-CoA reductase inhibitor used in hyperlipidemia and cancer research. Its lactone prodrug form is hydrolyzed in vivo to an active β-hydroxyacid that suppresses cholesterol biosynthesis and modulates cell cycle regulators. This article details its biological rationale, mechanism, application boundaries, and protocol parameters for robust experimental design.

447 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page